PatientsVille.com Logo

RHINORRHOEA and Zyrtec

PatientsVille

RHINORRHOEA Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for RHINORRHOEA

RHINORRHOEA treatment research studies

Zyrtec clinical trials, surveys and public health registries


Find Drug Side Effect reports



Zyrtec Side Effects

Pruritus (212)
Pain (145)
Fatigue (145)
Dizziness (140)
Somnolence (133)
Urticaria (132)
Dyspnoea (132)
Nausea (116)
Hypersensitivity (114)
Headache (113)
Insomnia (112)
Depression (105)
Feeling Abnormal (105)
Rash (103)
Anxiety (96)
Off Label Use (94)
Convulsion (93)
Product Quality Issue (92)
Condition Aggravated (80)
Abnormal Behaviour (79)
Loss Of Consciousness (43)
Aggression (43)
Overdose (41)
Withdrawal Syndrome (39)
Injury (39)
Pulmonary Embolism (38)
Irritability (36)
Vomiting (36)
Pyrexia (36)
Abdominal Pain Upper (35)
Deep Vein Thrombosis (34)
Hallucination (34)
Fall (34)
Asthma (33)
Diarrhoea (31)
Palpitations (30)
Malaise (30)
Suicidal Ideation (29)
Blood Pressure Increased (28)
Abdominal Pain (28)
Disturbance In Attention (27)
Cough (27)
Pain In Extremity (27)
Contusion (26)
Dry Mouth (26)
Chest Discomfort (26)
Anger (25)
Cholecystitis Chronic (25)
Weight Increased (25)
Back Pain (24)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Bad gastritis or abdominal pain; had to get into tub with hot shower on my belly;never had a worse experience or pain; thought I was going to die; malaise; moderate ear pain

Does Zyrtec inrease blood sugar levels? I have been taking 10m a day for 10 days and have notices symptoms of high blood sugar, when tested it was in the high 100's. Has anyone heard of this side effect?

Have you had him checked for P.A.N.D.A.S which is a syndrome related to strep throat. One major symptom can be sudden onset of Tourette's. ALso can cause OCD, depression, and other psychiatric conditions. My son has it. SOme doctors don't believe in

I have a 12 year old son who took Zyrtec for year-round allergies. He now has tourettes syndrome and westrongly feelthe Zyrtec played a role in this health issue. I started searching the web for info regarding

I have had and am having a bad reaction to Zyrtec. My eyes are inflamed and my throat is sore. Lips are swollen. My tongue is white. I will be forced to go to the Emergency at the hospital.

I have Type 2 Diabetes, when taking my level in the morning I noticed my level was elevated, and the only thing I had ingested was a Zyrtec pill about 2 hours prior? Could the pill be the cause?

I took one dose and experienced a bout of pancreatitis. I suffer from chronic pancreatitis and know what most of my 'triggers' are.....never thought a simple allergy medication would cause such a problem, I think I would rather suffer allergies than

I took Zyrtec for a week and while it does solve my allergy issues, it makes me a raving lunatic. Severe aggression, mood swings, and nightmares are the norm for me n this medicine. I would not recommend it if you are taking any a

Started on Zyrtec on the suggestion of my dermatologist for treatment of hives. Rash that resulted from the Zyrtec a MILLION times worse than the original hives. Had the same reaction to Seldane.

RHINORRHOEA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis
Conditions: Nasal Congestion and Inflammations;   Rhinitis
Interventions: Drug: Group 1;   Drug: Group 2
Outcome Measures: Improvement of nasal congestion and runny nose, after 48 hours of treatment;   Overall score of nasal and extranasal symptoms (nasal congestion, runny nose, sneezing, watery eyes and itching);   Clinical score of upper airway compromise;   Proportion of subjects who used at least once the rescue medication;   Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.
2 Unknown  Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis
Conditions: Nasal Congestion and Inflammations;   Rhinitis
Interventions: Drug: brompheniramine + phenylephrine;   Drug: Brompheniramine + pseudoephedrine
Outcome Measures: Improvement of nasal congestion and runny nose, after 48 hours of treatment;   Overall score of nasal and extranasal symptoms (nasal congestion, runny nose, sneezing, watery eyes and itching);   Clinical score of upper airway compromise;   Proportion of subjects who used at least once the rescue medication;   Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.
3 Unknown  A Randomized Double Dummy Double Blind Dose Determining Place-bo Controlled Study to Evaluate Efficacy of Investigational Product E-RH-06 at 2 Dose Levels for the Metabolic Management of Chronic or Recurrent, Non-infective Nasal Congestion With-or-without Rhinorrhea.
Condition: Chronic Rhinitis
Interventions: Dietary Supplement: E-RH-06;   Dietary Supplement: Placebo
Outcome Measures: TNSS Score;   Reduction of frequency
4 Recruiting Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu
Conditions: Upper Respiratory Tract Infection;   Nasal Congestion;   Rhinorrhea;   Sneezing
Interventions: Drug: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets;   Drug: Paracetamol (500 mg) tablets
Outcome Measures: Physician Global evaluation of effectiveness on Nasal Symptoms;   Sum of subject self assessment using a 100 mm Visual Analog Scale
5 Unknown  Middle Meatal Bacteriology During Acute Respiratory Infection in Children
Conditions: Acute Respiratory Infection;   Sinusitis
Interventions: Drug: placebo;   Drug: amoxicillin clavulanate acid
Outcome Measures: Duration of continuous daily symptoms of the acute respiratory infection diagnosed at the study entry.;   duration (days)and severity (grade mild, severe) of different symptoms (clear nasal discharge, coloured nasal discharge, nasal obstruction, cough, throat pain, ear ache, fever, headache, diarrhea);   number of days the child is using the following symptomatic drugs (pain killers, nasal vasoconstrictors, nasal corticosteroids, asthma drugs, antihistamines);   number of days the child is not at school and that the parents are not at work
6 Unknown  Efficacy and Safety Assessment of an Anti-Cold Preparation in the Symptomatic Treatment of Common Cold and Flu-Like Syndrome
Conditions: Common Cold;   Flu-like Syndrome
Interventions: Drug: Resfenol;   Drug: Placebo;   Drug: Co interventional acetaminophen
Outcome Measures: Symptom improval assessed by questionnaires concerning headache, muscle ache, rhinorrhea, nasal obstruction, sneezes, cough, sore or irritated throat, hoarseness and fever, rated by patient himself in a scale from 0 to 4, being 0-absence and 4-severe.;   Global duration of symptoms, assessed by the investigator through direct questioning at followup visits.;   Time of return to usual activities, such as work or gym, assessed by the investigator through direct questioning at followup visits.;   Use of co intervention for symptom relief during treatment, registered by the volunteer in patient diary, with day and hour of ingestion.;   Improval of fever by reduction of axillary temperature to less than 38,1°C.;   Adverse effect appearance during and until 7 days after treatment, assessed through patient's report in the diary or followup visit, through physical evaluation at followup and by laboratory exams.
7 Recruiting Effects of Pepper Gas Exposure in Non-combatant Bystanders.
Conditions: Cough;   Irritation in Throat;   Irritation in Skin;   Lacrimation
Intervention:
Outcome Measures: Development of cough, irritation in throat, nasal irritation, nasal discharge, wheezing, breathlessness, hemoptysis, chest pain upon exposure or worsening of already existing cough, breathlessness, wheezing of a previous respiratory illness.;   Duration of symptoms developed
8 Not yet recruiting Evaluation of the Efficacy and Safety of Two Ibuprofen Combination Products for the Treatment of the Common Cold and Flu in Latin America
Condition: Common Cold
Interventions: Drug: Advil Congestion Relief;   Drug: Advil Allergy and Congestion Relief;   Drug: Paracetamol
Outcome Measures: Change from baseline in the sum of 4 of the most common cold and flu symptoms (runny nose, plugged nose, sneezing and head congestion), averaged over 3 days obtained from the Wisconsin Upper Respiratory Symptom Survey - 21;   Change from baseline in the sum of all 10 symptoms, averaged over 3 days.;   AM assessment of symptom relief reflective over the past 12 hours.;   PM assessment of symptom relief reflective over the past 12 hours.;   Symptom relief since taking the first dose.
9 Recruiting NoAL (HPMC) in Combination With Oxymetazoline in Patients With Allergic Rhinitis
Condition: Allergic Rhinitis
Interventions: Drug: Oxymetazoline;   Other: Hydroxyl-propyl-methyl cellulose powder;   Other: Placebo (lactose powder)
Outcome Measures: Peak nasal inspiratory flow (PNIF) area under the curve (AUC) change between the placebo and active NoAl treatment on day 1;   Difference between the PNIF AUC D1-D8 differences between the two groups;   Differences in nasal mucociliary clearance (Saccharine test) between both groups.;   Visual analogue scale (VAS) for the separate rhinitis symptoms between the two groups;   Change of each symptom score for congestion over 8 days;   Change of total rhinitis symptom score (TRSS) over 8 days;   Difference in the applied rescue decongestant (total number of additional puffs of oxymetazoline or any other medications indicated for the treatment of allergic rhinitis) as needed between the two groups;   Number and severity of adverse events
10 Recruiting MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (8237-009)
Conditions: Allergic Rhinitis;   Allergic Rhinoconjunctivitis
Interventions: Biological: MK-8237;   Other: Placebo
Outcome Measures: Change from baseline in HDM-specific IgG4 antibodies in serum at 12 weeks;   Change from baseline in HDM-specific IgE-BF in serum at 12 weeks;   Change from baseline in 6 hours post-NAC Interleukin-5 (IL-5) protein concentration in nasal exudates following 12 weeks of treatment;   Change from baseline in 6.5 hours post-NAC nasal epithelial eosinophil-related messenger RNA (mRNA) signature following 12 weeks of treatment;   Change from baseline in 1-6 hours post-NAC visual analog score (VAS) for sneezing, rhinorrhea, congestion and nasal itch following 12 weeks of treatment
11 Not yet recruiting The Optimal Head Position for Distributing Topical Nasal Medication Using the Mucosal Atomization Device
Condition: Sinusitis
Interventions: Procedure: Lying Head Back Position;   Procedure: Head Down and Forward Position
Outcome Measures: Endoscopic sinonasal mucosal inflammation;   Quality of Life (via SNOT-22)
12 Unknown  Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis
Conditions: Inflammation;   Cough;   Rhinitis
Interventions: Drug: diphenhydramine + dropropizine + pseudoephedrine;   Drug: Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).
Outcome Measures: Improvement of nasal congestion and cough;   Improvement of non-obstructive nasal symptoms;   Reduction of the frequency of nighttime awakenings of parent/guardian/roommate of the child;   Reduction of vomiting frequency episodes triggered by coughing;   Improvement of acute rhinitis signs;   Use of rescue medication;   Overall impression of improvement by the investigator;   Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.
13 Unknown  Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Diphenhydramine + Pseudoephedrine + Dropropizine in the Control of Cough and the Relief of Nasal Symptoms, Suffering From Non-productive Cough and Acute Rhinitis
Conditions: Nasal Congestion;   Cough
Interventions: Drug: Group 1;   Drug: Group 2
Outcome Measures: Primary efficacy criteria;   Secondary efficacy criteria
14 Unknown  Postoperative Nasal Irrigation Using Mucolytic Agents
Condition: Surgical Procedure, Unspecified
Interventions: Drug: saline nasal irrigation alone;   Drug: dissolved N-Acetylcystine
Outcome Measures: change in QOL based on the Sino-Nasal Outcome Test-22 (SNOT-22) scores;   Lund-Kennedy endoscopic score (LKES)
15 Recruiting Intranasal Dexmedetomidine Premedication
Condition: Benign Neoplasm of Vocal Fold - Glottis
Interventions: Drug: Dexmedetomidine;   Drug: placebo
Outcome Measures: Extubation time after intranasal dexmedetomidine premedication;   Sedation level;   The occurrence of perioperative adverse events;   Hemodynamic responses
16 Recruiting Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)
Conditions: Mucopolysaccharidosis;   Mucopolysaccharidosis I;   Mucopolysaccharidosis II;   Mucopolysaccharidosis VI
Intervention:
Outcome Measures: The status of diagnosis of MPS II (either positive or negative) of each subject;   The status of diagnosis of MPS I or VI (either positive or negative) of each subject
17 Recruiting Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)
Conditions: Asthma, Aspirin-Induced;   Aspirin Exacerbated Asthma
Intervention: Drug: Prasugrel
Outcome Measures: Change in Total Nasal Symptom Score(TNSS)from baseline to aspirin challenge/desensitization.;   Change from baseline expression levels of COX-2 transcript and protein in peripheral blood leukocytes of subjects with AERD after 8 weeks of treatment with aspirin.;   Difference in participant's provocative dose of aspirin when pretreated with prasugrel versus placebo;   Change in urinary LTE4;   Effect desensitization to and treatment with aspirin has on baseline characteristics of AERD
18 Recruiting Postoperative Systemic Corticosteroids When Utilizing a Steroid-Eluting Spacer Following Endoscopic Sinus Surgery
Conditions: Chronic Sinusitis;   Endoscopic Sinus Surgery;   Post-operative Care;   Steroids;   Drug-eluting Spacer
Interventions: Device: Steroid-eluting middle meatal spacer (Nasopore (TM) spacer impregnated with 1 cc of 40mg/mL triamcinolone liquid);   Drug: Post-op Oral Steroids
Outcome Measures: Health Related Quality of Life Score (based on SNOT-22, VAS, and RSDI questionnaires);   Sinus mucosal disease endoscopic grading score (based on Lund-Kennedy and POSE Scoring systems)
19 Recruiting Evaluating the Impact of Chronic Rhinosinusitis on the Health-Related Quality of Life Among Adults With Cystic Fibrosis
Condition: Cystic Fibrosis
Intervention: Behavioral: Cystic Fibrosis Questionnaire (Revised) for Teens/Adults
Outcome Measure: Difference in Cystic Fibrosis-specific HRQoL score among those with and without CRS.
20 Unknown  The Relationship Between Allergic Rhinitis and Geographic Tongue
Conditions: Allergic Rhinitis;   Geographic Tongue
Intervention:
Outcome Measure: Number of participants with Adverse Events